10-Q quarterly report · filed Nov 4, 2026

agilon health, inc. (AGL) Q3 2026 10-Q Quarterly Report

Short answer

agilon health, inc. (AGL) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $1.5B (up 5.9% year over year) with net income of $35M.

Q3 2026 key financials · XBRL

Revenue
$1.5B
+5.9% YoY · +1.7% QoQ
Net income
$35M
+131.7% YoY · +94.4% QoQ
Operating margin
1.6%
EPS (diluted)
$1.96
+92.2% QoQ

Source: XBRL data from the agilon health, inc. (AGL) Q3 2026 10-Q on SEC EDGAR. USD.

agilon health, inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $1.52B, up 6% YoY from $1.43B, driven by higher PMPM capitation rates and premium yield
  • MSER 88.5% vs 104.0% YoY, with medical services expense down 10% to $1.34B
  • Best performance: profitable geographies, physician incentive expense $54.9M vs $(18.2)M YoY
  • Net income $34.9M vs $(110.2)M; Adjusted EBITDA $63.7M vs $(91.5)M
  • Cash and restricted cash $246.4M, marketable securities $65.4M; nine-month operating cash flow $16.3M vs $(85.2)M

Risk Factors

  • Newly triggered liquidity risk: Third Amendment requires minimum Total Cash of $50.0 million daily and 100% cash collateralization of letters of credit
  • Most materially updated debt risk: Term-loan maturity extended to February 18, 2028, while revolving commitments fell to $90.0 million
  • Regulatory and compliance risk: CMS risk-adjustment settlements typically arrive 12 to 18 months later, creating revenue reversal exposure
  • Operational risk: Company bears full medical-cost risk for approximately 453,600 Medicare Advantage members
  • Financial concentration risk: Substantially all receivables come from a small number of payors

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other agilon health, inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.